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Introduction {#sec005}
============

Human Respiratory Syncytial Virus (hRSV) is an enveloped, non-segmented, single stranded negative sense RNA pneumovirus of the paramyxoviridae family that causes lower airway respiratory disease in preterm newborns, term newborns, and elderly adults \[[@pone.0143580.ref001], [@pone.0143580.ref002]\]. It is the most important viral pathogen causing acute lower respiratory tract infections (ALRI) in infants younger than 5 years old and it is estimated to have resulted in \~3.4 million hospitalizations and \~200,000 deaths worldwide in 2005 \[[@pone.0143580.ref003]\]. RSV is transmitted by direct and indirect contact of nasal or oral secretions from an infected individual and primarily targets the lower airway respiratory epithelium (bronchioles) \[[@pone.0143580.ref004]\]. Clinical signs in infants and in children develop four to six days after infection with RSV, and usually subside after one to two weeks \[[@pone.0143580.ref005]\]. These signs vary with severity of disease and range from mild flu-like symptoms (coughing, sneezing, fever, and loss of appetite) in 25% to 40% of first-time exposed infants to severe bronchiolitis with or without pneumonia (rapid breathing, difficulty breathing, and wheezing) necessitating hospitalization in 0.5% to 2% of infants\[[@pone.0143580.ref006]\]. In very young infants, irritability, decreased activity, and apnea may be the only symptoms of infection. These clinical symptoms have been attributed to both the immune response to RSV, as well as the direct damage to RSV-infected bronchiolar epithelium \[[@pone.0143580.ref007], [@pone.0143580.ref008]\].

Current treatment of RSV infection is limited to supportive care. There exists an inhaled nucleoside analog (Ribavirin) that is approved for therapeutic use but which has limited treatment efficacy, as well as a monoclonal antibody (Synagis^®^, palivizumab), but whose use is limited to prophylactic application in high risk infants \[[@pone.0143580.ref009]\]. Two major hurdles in the development of preventative and therapeutic regimens are (i) the safety considerations following vaccination in young infants exemplified by the disastrous initial formalin-inactivated vaccine clinical trials where vaccination potentiated the disease rather than being protective and (ii) the lack of an available, clinically relevant model of RSV infection \[[@pone.0143580.ref010]\].

Animal models developed to study RSV infection include mice, cotton rats, ferrets, non-human primates, cattle, and lambs \[[@pone.0143580.ref009]\]. Lambs have several biological features that closely mimic RSV infection in human infants such as: similarities to human infants in lung development, lung structure and airway branching, cellular composition and immune responses, survival after late-preterm birth, susceptibility to various strains of RSV including human strains (Long, A2, and Memphis Strain 37), similar histologic lesions and lung size to human infants, and the ability to obtain lambs lacking maternal antibodies \[[@pone.0143580.ref011]--[@pone.0143580.ref015]\]. Despite these advantages and the many previous and on-going studies of RSV infection in lambs, the progressive development of clinical signs, lung pathology and inflammatory/immune responses over time after inoculation with a human strain of RSV have not been fully characterized. Thus, the aim of this study was to gain further insight and understanding of the effects of RSV infection in the neonatal lamb model throughout infection (days 1, 3, 4, 6 and 8 after inoculation) with the human RSV Memphis Strain 37. This kinetic information is needed in order to more fully characterize and utilize the lamb model for therapeutic and vaccine studies.

Material and Methods {#sec006}
====================

Experimental design {#sec007}
-------------------

Colostrum-deprived neonatal lambs (2--7 days of age) received daily antibiotics (Ceftiofur, Pfizer, New York, NY; 1--2 mg/kg, intramuscular) to prevent secondary bacterial infections. They were randomly assigned to five M37 hRSV-infected groups, of 3 lambs (n = 3). Each lamb received three 2-mL installments of 1.27 x 10^7^ FFU/mL in DMEM over a 23-minute period using a PARI LC Sprint^™^ nebulizer (PARI Respiratory Equipment, Inc., Lancaster, PA, USA) at 4L/min at 16 PSI (Philips Respironics Air Compressor, Andover, MA, USA) attached to a conical mask fitted with a round rubber diaphragm with a pre-cut center hole through which the nose and mouth of the lamb was inserted (MidWest Veterinary Supply, Inc., Burnsville, MN). Following infection, lambs were euthanized by sodium pentobarbital overdose and necropsied at different days post viral infection (p.i.): days 1, 3, 4, 6, and 8 p.i. After euthanasia the thorax was opened, lungs were removed, and RSV gross lesions (not including bacterial pneumonia lesions) were scored and photographed *ex vivo*. Tissue samples were collected from each lung lobe of all animals in the same manner, with uniform sampling of each lobe, and avoiding areas of bacterial pneumonia. Before lung dissection, bronchoalveolar lavage fluid (BALF) was collected from the right caudal lung lobe for infectious Focus-Forming Unit (FFU) assay and RT-qPCR for M37 hRSV total nucleoprotein RNA and accessory lobe, for cytology (total and differential cell counts), as described below. Three samples from each lobe were snap frozen in liquid nitrogen for reverse transcription quantitative polymerase chain reaction (RT-qPCR), and two samples from each lobe were placed in tissue cassettes and put in 10% neutral-buffered formalin for histological and immunohistochemical analyses.

Due to limitations in housing and number of lambs that can be handled in one study, the day 6 assessments were derived from an additional group of 3 lambs that was infected shortly after the necropsy of the other groups. The procedures, viral stock used and animal handling were identical to the viral kinetic (VK) study. The only difference was that the day 6 animals were slightly younger and lighter than the VK study animals as these came from another supplier (mean bodyweights of 3.4 ± 0.17 vs 6.3 ± 0.24 for the VK study on day 0; mean± se). In accordance to the 3R-principles, control lambs were not included in this study as previous work in our lab showed that non-infected lambs entirely lacked evidence of clinical illness, lung pathology, or immune and inflammatory changes that are consistent with M37 hRSV infection \[[@pone.0143580.ref001], [@pone.0143580.ref016]--[@pone.0143580.ref020]\]. Animal use and experimental procedures were approved by Iowa State University's Animal Care and Use Committee (IACUC).

Virus {#sec008}
-----

Memphis 37 (M37) RSV is a wild type RSV-A, first isolated from a 4 month old infant \[[@pone.0143580.ref021]\] and used in human clinical studies \[[@pone.0143580.ref022]--[@pone.0143580.ref024]\]. The Memphis 37 RSV strain used in this study was passaged 6 times on Vero cells then twice on HEp-2 cells. Sucrose was added to 20% and the virus stock was frozen at −80°C and titered for infectivity on HEp-2 cells as we have characterized previously in this model \[[@pone.0143580.ref020]\].

Monitoring of clinical signs {#sec009}
----------------------------

Lambs were monitored daily for body weights, rectal temperatures, heart rate and percent blood oxygenation measurements (PalmSAT^®^ 2500A VET pulse oximeter, Nonin Medical Inc., Plymouth, MN, USA), and manual heart and respiratory rates (by auscultation). Increased expiratory effort (forced expiration) was scored daily as were animal "wheeze" scores ([Table 1](#pone.0143580.t001){ref-type="table"}).

10.1371/journal.pone.0143580.t001

###### Scoring criteria for lung function by auscultation.

![](pone.0143580.t001){#pone.0143580.t001g}

  Score   Expiratory efforts                                                        Wheezing (High-pitched whistling sound made while breathing)
  ------- ------------------------------------------------------------------------- --------------------------------------------------------------
  0       No expiratory effort                                                      No wheeze
  1       Earliest detection of increased expiratory effort                         Earliest detectable wheeze by auscultation
  2       Moderate expiratory effort (\>1sec) observed with some abdominal effort   Audible wheeze in all lung fields by auscultation
  3       Expiratory effort (\>3 sec) with hard abdominal effort                    Wheeze audible without stethoscope

Collection of nasal wash fluid (NWF) {#sec010}
------------------------------------

Just before euthanasia the nasal cavity of each lamb was washed with double-modified Iscove's medium (DMIM) containing 42.5% Iscove\'s modified Dulbecco\'s medium, 7.5% glycerol, 1% heat-inactivated FBS, 49% Dulbecco's Modified Eagle medium (DMEM), and 5 μg/mL kanamycin sulfate. Using a 6-mL syringe fitted with a mucosal atomization device (MAD) conical foam end-piece (Intranasal Mucosal Atomization Device, Wolfe Tory Medical, Inc., Salt Lake City, UT, USA) a single 5 mL aliquot of DMIM was instilled into the right nare, and then (while still preserving a good seal between the nare and the MAD-device conical end-piece), any out-coming fluid was extracted fairly quickly, in one motion, back into the delivery syringe to collect (1.3--2.5 mL) NWF; which was dispensed into a 15 mL conical tube and placed on ice.

Collection of bronchoalveolar lavage fluid (BALF) {#sec011}
-------------------------------------------------

Following euthanasia the lungs of each lamb were removed and each left and right lung was separated and weighed. The excised right caudal lung lobe was instilled with 5 mL of cold DMIM (42.5% Iscove\'s modified Dulbecco\'s medium, 7.5% glycerol, 1% heat-inactivated FBS, 49% DMEM, and 5 μg/ml kanamycin sulfate) after which 1 mL of the resulting BAL fluid was placed on ice and spun down for 5 minutes in a centrifuge at 3,000 x g to pellet large debris. Approximately 800--850 μL of each supernatant was collected and then spun through 850 μL-capacity 0.45 μm Costar SPIN-X filter (microcentrifuge 15,600 x g) for 5 minutes before being used in the standard infectious focus forming unit assay (FFU).

Gross lesions evaluation and scoring {#sec012}
------------------------------------

Following euthanasia, the thorax was opened and the heart and esophagus were removed from the lungs. The percentage parenchymal involvement of gross RSV lesions was scored for each individual lung lobe, and if present, the area and amount of lung lobes affected by bacterial pneumonia was also recorded. The percentage of a specific lobe tissue that was affected by RSV in relation to the overall lobe tissue being scored was estimated based on a score as done previously \[[@pone.0143580.ref001]\]. Mean percentage averages per lobe were calculated for each day of necropsy.

Histologic evaluation and scoring {#sec013}
---------------------------------

A histologic score was given by determining percent involvement followed by conversion to an additional integer-based consolidation scale used by our laboratory previously \[[@pone.0143580.ref001]\] wherein: 0% consolidation = 0; 1%-9% consolidation = 1; 10%-39% consolidation = 2; 40%-69% consolidation = 3; 70%-100% consolidation = 4. In total, multiple fields from 4 slides per animal were scored for the lesions. Each slide contained 2 different sections from the same lobe. Histologic score for each animal was the mean of all 4 slides and group averages were calculated for the alveolar consolidation score. In addition to the consolidation score, bronchitis/bronchiolitis, neutrophil infiltration, peribronchiolar and perivascular infiltration of lymphocytes, syncytial cell formation, and epithelial alterations were also scored according to criteria indicated in [Table 2](#pone.0143580.t002){ref-type="table"}.

10.1371/journal.pone.0143580.t002

###### Histologic lung lesion scoring criteria.

![](pone.0143580.t002){#pone.0143580.t002g}

  Score   Bronchitis                                                                          Bronchiolitis                                                                                                                                            Syncytial cells                       Epithelial necrosis (bronchi or bronchioles)         Epithelial hyperplasia (bronchi, bronchioles)                Neutrophil (in bronchi, bronchioles or alveoli)          Bi nodules (these are peribronchiolar lymphocytic infiltrates)       Vessel nodules (lymphocytic infiltrates around blood vessels)        Eosinophilic infiltrates in bronchi or bronchioles, alveoli              Eosinophilic infiltrates in vessels               Eosinophils in vessel lumens
  ------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ---------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------- ------------------------------------
  0       no remarkable lesions                                                               no remarkable lesions                                                                                                                                    none                                  none                                                 none                                                         none                                                     none                                                                 none                                                                 none                                                                     none                                              none
  1       minimal detectable lymphoplasmacytic infiltrates in lamina propria and adventitia   minimal detectable lesion (epithelial degeneration) in one or a few bronchioles per 20x field                                                            one distinct syncytial cell           minimally detectable in one or a few per 20x field   minimally detectable in one or a few airways per 20x field   minimally detectable                                     earliest detectable lymphocytic infiltrates in the adventitia        earliest detectable lymphocytic infiltrates in the adventitia        minimally detectable                                                     minimally detectable                              minimally detectable
  2       segmental to circumferential infiltrates                                            epithelial degeneration involving less than 10% of the airway lumen; minimal neutrophils, cell debris; adventitial lymphocytes in multiple bronchioles   up to three in three 20x fields       10% in multiple airways per 20x field                10% of airway per 20x field                                  10 or less neutrophils in one or a few airways/alveoli   segmental to circumferential infiltrates                             segmental to circumferential infiltrates                             up to five eosinophils in one to several airways/alveoli per 20x field   up to five eosinophils associated with a vessel   up to five in one or a few vessels
  3       dense infiltrates                                                                   epithelial degeneration involving \>10--50% of the airway lumen with cell debris, neutrophils; adventitial lymphocytes; multiple bronchioles             more than three in three 20x fields   10--50% in multiple airways per 20x field            10--50% in multiple airways per 20x field                    10 or more neutrophils in several airways/alveoli        circumferential infiltrates that expand more than three cells wide   circumferential infiltrates that expand more than three cells wide   over five in over five airways per 20x field                             \> five in over five vessels per 20x field        \> five in over five vessels
  4       infiltrates with nodular aggregates                                                 circumferential bronchiolitis with dense adventitial lymphocytes; multiple bronchioles                                                                   Numerous in three 20x fields          circumferential in multiple airways                  circumferential                                              10 or more involving many/most airways/alveoli           circumferential infiltrates that form nodules                        circumferential infiltrates with nodules                             dense accumulations of eosinophils                                       dense accumulations of eosinophils                dense accumulations

Immunohistochemistry for viral antigen detection {#sec014}
------------------------------------------------

Immunohistochemistry for the detection of RSV antigen was performed on 5 μm-thick formalin-fixed paraffin-embedded (FFPE) lamb lung tissue sections taken from the right and left cranial, left middle, and left caudal lung lobes of each animal in accordance with methods published previously \[[@pone.0143580.ref017], [@pone.0143580.ref025]\], but with the following variations: instead of Pronase E antigen retrieval, heated buffer antigen retrieval was performed in TRIS-EDTA-0.05% Tween 20, pH 9.0 in a pressure cooking device (Decloaking Chamber^™^ Plus, Biocare Medical, Concord, CA) using the factory default 40-minute program (125°C reached in 18 minutes and cooling to 80°C in another 22 minutes). Primary polyclonal goat anti-RSV (all antigens) antibody (EMD Millipore Corporation, Billerica, MA, USA) was applied for 90 minutes at room temperature diluted 1:500 in TBS-tween containing 10% NSS and 3% BSA. After rinsing with TBS-tween, biotinylated rabbit anti-goat secondary antibody (Kirkegaard-Perry Labs, Gaithersburg, MD, USA) diluted 1:300 in TBS-tween containing 10% NSS and 3% BSA was applied for 45 minutes, after which slides were rinsed with TBS-tween, treated with 3% H~2~O~2~ in TBS-tween for 25 minutes, rinsed and then incubated with streptavidin-conjugated HRP (Invitrogen) diluted 1:200 in TBS-tween for 30 minutes. Development of the color was performed in custom 12-slide plastic containers (Antibody Amplifier^™^ containers, ProHisto, LLC, Columbia, SC, USA) by applying Nova Red (Vector Laboratories, Inc.) for about 90 seconds followed by copious rinses with ddH~2~O, counterstaining with Harris' hematoxylin (for 2 minutes), bluing with alkaline Scott's water (for 1 minute), dehydration and coverslipping with Permount mounting medium (Sigma, St. Louis, MO, USA). 20 unique 10X fields on each slide (containing two lung sections each) were assessed for RSV antigen staining by counting positively-stained cells within bronchioles and alveoli. The mean number of stained bronchi/bronchioles and alveoli per field were counted for each day of necropsy.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) assessment of RSV and chemokine gene mRNA expression levels in lamb lung {#sec015}
-----------------------------------------------------------------------------------------------------------------------------------------------

For each animal, tissue samples from right and left cranial, left middle and left caudal lung lobes (0.3--0.4 g of each lobe) were homogenized for total RNA isolation in TRIzol (Invitrogen) and previously described methods \[[@pone.0143580.ref001]\]. RNA was assessed for quantity and purity by spectrometry (Beckmann DU^®^ 640B, Beckmann Coulter Inc., Brea, CA, USA) and all OD~260nm/280nm~ values measured between 1.96 and 2.12. Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) analysis of RNA prior to DNase treatment consistently yielded RIN values ≥8.0 for all lamb lung RNA samples isolated this way \[[@pone.0143580.ref016]\]. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed using One-Step Fast qRT-PCR Kit master mix (Quanta, BioScience, Gaithersburg, MD, USA) in a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) and PREXCEL-Q for all set up calculations \[[@pone.0143580.ref026], [@pone.0143580.ref027]\]. Primer and probe sequences for all targets were designed with ABI Primer Express 2.0, and have been used previously \[[@pone.0143580.ref001], [@pone.0143580.ref017], [@pone.0143580.ref028]\]. Primers and hydrolysis probe for targeting M37 hRSV NP RNA were designed using ABI Primer Express version 2.0 based on RSV accession number M74568. Thermocycling conditions were 5 minutes at 50°C; 30 seconds at 95°C; and 45 cycles of 3 seconds at 95°C and 30 seconds at 60°C. Samples and standards were assessed in duplicate, and each target gene quantification cycle (Cq) value was converted to a relative quantity (Q~r~) based on each target's standard curve using: Q~r~ = E~AMP~ ^(b-Cq)^, wherein "b" and "E~AMP~" are the y-intercept and exponential PCR amplification value, respectively. E~AMP~ values were obtained from the slope (m) of each target standard curve by: E~AMP~ = 10^(-1/m)^, and all Q~r~ values interpolated from standard curves were normalized to total lung RNA per RT-qPCR (0.784 ng RNA/μL for all reactions). No-RT control (NRC) reactions gave either no signal or generated Cq values greater than 13 cycles later than those in the corresponding RT-qPCR target reactions.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV in nasal wash fluid and bronchoalveolar lavage fluid {#sec016}
-----------------------------------------------------------------------------------------------------------------------------------

Viral RNA was quantified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in NWF and BALF obtained from each animal at necropsy. NWF was obtained from the right nasal cavity and BALF from the right caudal lung lobe of each animal (see section on NWF and BALF collection). Briefly, 100 μL of each collected fluid sample was pipetted directly into 1 mL of TRIzol (Invitrogen/Life Technologies, Carlsbad, CA, USA) on ice, inverted to mix, and then transferred to -80°C for storage until RNA isolation and subsequent RT-qPCR. Upon thawing, each 1.1 mL sample was vortexed for 10 seconds and allowed to sit at room temperature for 10 minutes. RNA isolation from NWF and BALF samples continued as per manufacturer's instructions. The resulting (non-visible) RNA pellets, were each dissolved in 100 μL of nuclease-free water (Invitrogen/Life Technologies), vortexed thoroughly, microfuged briefly, warmed to 60°C for 3 minutes, vortexed for 5 seconds, microfuged briefly, then 80 μL of each was diluted 1:10 with a combination of 10 μL RNaseOUT^™^ (to 0.5 Units/ μL), and 710 μL nuclease-free water, then stored at 4°C prior to RT-qPCR. RT-qPCR for RSV was then carried out as described above in the section: "Reverse transcription quantitative polymerase chain reaction (RT-qPCR) assessment of RSV and chemokine gene mRNA expression levels in lamb lung".

Focus-forming unit (FFU) assay {#sec017}
------------------------------

Viral titers in both nasal wash fluid (NWF) and bronchoalveolar lavage fluid (BALF) from the right lung caudal lobe were determined using an infectious focus assay (FFU). In brief, 200 μL of serially-diluted NWF or BALF samples were applied to HEp-2 cells grown to 70% confluence in 12-well culture plates (Fisher Scientific, Hanover Park, IL) in DMEM media (Mediatech, Inc., Manassas, VA) supplemented to 10% with heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 50 μg/mL kanamycin sulfate (Invitrogen/Life Technologies). Each sample was analyzed undiluted and at four additional serial-dilutions of 1:10, 1:100, 1:1,000 and 1:10,000 in duplicate. Following a 48-hour incubation at 37°C, 5% CO~2~, the cells were fixed with cold 60% acetone/40% methanol solution for 1 minute. Overnight primary polyclonal goat anti-RSV (all antigens) antibody (EMD Millipore Corporation, Billerica, MA, USA) incubation was followed by washing and secondary antibody (Alexa Fluor^®^ 488 F(ab')2 fragment of rabbit anti-goat IgG (H+L), Molecular Probes/Life Technologies) incubation for 30 minutes. Plates were rinsed and inspected for the presence of fluorescing foci of infection using the FITC/GFP filter on an inverted fluorescence microscope (Olympus CKX41, Center Valley, PA). Five or more fluorescing cells were counted as single focal events. An average of 40 counts in a 1:10-diluted (duplicate) sample indicated an original NWF or BALF sample "titer" of 2,000 \[40 counts x dilution of 10 x 1,000 μL/mL\]/200 μL assessed = 2,000 infectious focus-forming units/mL (FFU/mL).

Results {#sec018}
=======

Clinical findings {#sec019}
-----------------

Following RSV-infection, there were no differences in weight gain, body temperature, heart rate, and percent blood oxygen saturation when compared to control lambs from previous studies in which the procedures, facilities, animal handling, and source and age of lambs were similar \[[@pone.0143580.ref001], [@pone.0143580.ref016]--[@pone.0143580.ref020]\]. Despite a small drop in mean blood oxygen saturation levels on day 6 (92.4% ± 2%; mean ± SD) when respiratory distress was present in most lambs, these remained above the 90% limit. Respiratory rates (not shown) were variable and non-predictable for each day of the study and were likely confounded by the heavy sampling schedule and the resultant stress level of the newborn lambs. Increased expiratory efforts and wheezing were the only noteworthy clinical features observed in RSV-infected lambs in this study. Following inoculation with M37 hRSV, expiratory efforts became apparent on day 3 in 4 out of 12 lambs (33%). On day 5 this proportion increased to 4 out of 6 lambs (66%) and on day 6 to 5 out of 6 lambs (83%). By day 7 all lambs (100%) had increased expiratory efforts, but on day 8 this proportion dropped to 2 lambs out of 3 (66%). The severity of expiratory efforts increased from day 3 to day 7 as shown by the mean expiratory effort score ([Fig 1A](#pone.0143580.g001){ref-type="fig"}). Similarly, wheezing was apparent on day 3 although only in 1 out of 12 lambs (8.3%). The proportion of lambs that developed wheeze gradually increased to reach a peak on day 5 (83.3%) and decreased on day 8 (33%). The mean wheeze score followed a similar time profile ([Fig 1B](#pone.0143580.g001){ref-type="fig"}).

![Respiratory distress score of lambs inoculated with human respiratory syncytial virus (hRSV) strain Memphis 37 (M37).\
Respiratory distress score was assessed daily for each lamb by auscultation or visual observation, and was categorized by expiratory effort **(A)** and wheezing **(B)**. Results are shown as mean ± standard error.](pone.0143580.g001){#pone.0143580.g001}

Gross and microscopic lung lesions {#sec020}
----------------------------------

Following necropsy, gross examination of the lungs determined the percent of each lobe that was covered with typical RSV-induced lesions. In some cases, areas of lung with lesions suggestive of bacterial pneumonia were also present along with RSV-induced lesions, and lung lobes with lesions suggestive of bacterial pneumonia were recorded, but not scored as RSV lesions. RSV lesions were bilateral, evenly-distributed and characterized by multifocal to locally extensive dark plum-red, well-demarcated foci of pulmonary consolidation which varied from mild to severe ([Fig 2A](#pone.0143580.g002){ref-type="fig"}); consistent with RSV infection in lambs as reported previously \[[@pone.0143580.ref001], [@pone.0143580.ref017], [@pone.0143580.ref029]\]. In contrast to RSV lesions, lung lobes affected by bacterial pneumonias were mild, unilateral, and cranial ventral (right and middle lung lobes being mostly affected), and were characterized by multifocal, locally extensive, firm, red-brown areas. Following RSV-infection, gross RSV viral lesions were already detectable on day 1, and further increased by day 3, to reach maximal levels by day 6 of around 40% and decreased thereafter ([Fig 2B](#pone.0143580.g002){ref-type="fig"}). For the lambs used in this study, only the last group of lambs (10 and 12) necropsied at day 8, had gross lesions of bacterial pneumonia affecting the right middle lung lobe. For day 6 lambs, lamb 14 had bacterial pneumonia affecting the right cranial and middle lung lobes. Again, these lung regions bearing non-RSV-induced lesions were not sampled for attaining experimental endpoints.

![Viral gross lesions caused by M37 hRSV infection in neonatal lambs.\
**(A)** Picture of a lung on day 6 post-infection. Dark plum-red, well-demarcated foci of pulmonary consolidation are indicated by arrowheads. **(B)** Percentage parenchymal involvement was estimated for each lung lobe and mean percentage averages per lobe were calculated for each day of necropsy (± standard error). Legend: Rt Cr = Right cranial lobe; Rt Mid = Right Middle lobe; Rt Cd = Right Caudal lobe; Acc = Accessory lobe; Lt Cr = Left Cranial lobe; Lt Mid = Left Middle lobe; Lt Cd = Left Caudal lobe.](pone.0143580.g002){#pone.0143580.g002}

Microscopically, lungs of infected lambs had multifocal to coalescent foci of an inflammatory infiltrate that partially filled the lumen of bronchi/bronchioles, alveolar spaces, and alveolar septa. The airway lumen was also partially occluded by seroproteinaceous fluid and cell debris intermixed with mucin. These lesions increased progressively with time and were similar to those described previously with M37 hRSV and with hRSV A2 strains \[[@pone.0143580.ref001], [@pone.0143580.ref017], [@pone.0143580.ref018], [@pone.0143580.ref025]\]. On day 1 p.i., small numbers of neutrophils were present within the lumen of bronchioles and occasional bronchi. On day 3, microscopic lung lesions were characterized by mild to moderate infiltrates of neutrophils in bronchiolar lumens with small amounts of seroproteinaceous fluid and mucin. A mild but detectable infiltration of lymphocytes in the tunica adventitia of bronchioles and nearby blood vessels was also present. There was degeneration (cells with rounded cell borders and basophilic/pyknotic nuclei) of epithelial cells in bronchioles ([Fig 3A](#pone.0143580.g003){ref-type="fig"}). The intensity of the lesions were further increased on day 4 and characterized by the neutrophil infiltration with sloughed, necrotic epithelial cells, seroproteineous fluid and small amounts of mucin in bronchioles and bronchi along with occasional macrophages and the formation of occasional syncytial cells in bronchio-alveolar spaces. The alveolar septa were mildly to moderately thickened by hyperplasia of type II pneumocytes and the bronchioles were surrounded by moderate to mild numbers of lymphocytes and plasma cells; a few lymphocytes were present within the alveolar septa. By day 6, all observed lesions present on day 4 peaked, with the notable exception of lymphocytic infiltration in the peribronchiolar region and blood vessels. Neutrophils were prominent on day 6 p.i. but reduced/absent on day 8 p.i. which is consistent with our previous studies in the lamb model \[[@pone.0143580.ref017], [@pone.0143580.ref028]\]. Peribronchiolar and perivascular lymphocyte infiltration was increased on day 8 while all other parameters were reduced ([Fig 3B](#pone.0143580.g003){ref-type="fig"}).

![Microscopic lung lesions severity score in M37 hRSV infected neonatal lambs.\
**(A)** Histopathologic lesions included bronchiolitis with degenerate/necrotic individual epithelial cells (thin arrow), occasional syncytial cells (long arrow), accumulation of degenerate neutrophils (short arrow), and occasional macrophages. H&E Bar = 50 μm. **(B)** A histologic score was given by determining percent consolidation followed by conversion to an integer-based consolidation scale used by our laboratory previously \[[@pone.0143580.ref001]\]: 0% consolidation = 0; 1%-9% consolidation = 1; 10%-39% consolidation = 2; 40%-69% consolidation = 3; 70%-100% consolidation = 4. Group averages were calculated for alveolar and bronchiolar consolidation scores. In addition to the consolidation score, bronchitis, bronchiolitis, neutrophil infiltration, peribronchiolar and perivascular infiltration of lymphocytes, syncytial cell formation, and epithelial alterations were also scored. Results are indicated as mean ± standard error for each scored parameter.](pone.0143580.g003){#pone.0143580.g003}

Viral titers, viral RNA levels and viral antigen expression {#sec021}
-----------------------------------------------------------

Levels of M37 hRSV total nucleoprotein RNA in lung tissue, BALF, and NWF were measured by RT-qPCR, while cultivatable virus was quantified by infectious focus (FFU) assay in NWF and BALF collected on each day of necropsy. Viral titers and viral RNA in BALF and lung tissue increased progressively from day 1 to day 3 and were sustained or increased slightly until day 6. On day 8, viral titers and RNA decreased substantially as observed for all other virology endpoints (viral antigen expression, gross lung lesions, and microscopic lesions). In contrast, viral titers and viral RNA levels in NWF were more variable when comparing them to levels in BALF and lung tissue. Viral titers in NWF were highest at day 3 (1.7 log~10~ FFU/mL), whereas this was the case on day 6 (2.9 log~10~ RNA copies/mL) for viral RNA. Overall, intranasal viral replication was substantially lower than viral replication in the lung ([Table 3](#pone.0143580.t003){ref-type="table"}) and may be due to the administration of virus by nebulization which may bypass the nose to some extent or be indicative of a lower permissiveness of lamb nasal epithelial cells for RSV replication.

10.1371/journal.pone.0143580.t003

###### Quantification of RSV replication via RT-qPCR and infectious focus assay in lambs inoculated with M37 hRSV.

![](pone.0143580.t003){#pone.0143580.t003g}

              Viral load (Nasal Washes)[\*](#t003fn001){ref-type="table-fn"}   Viral load (BALF)[\*](#t003fn001){ref-type="table-fn"}   Viral transcripts(Lung tissue)                 
  ----------- ---------------------------------------------------------------- -------------------------------------------------------- -------------------------------- ------------- -------------
  **Day 1**   BDL (0.7)                                                        1.44 ± 1.1                                               2.53 ± 0.09                      3.80 ± 0.03   4.81 ± 0.15
  **Day 3**   1.7 ± 0.4                                                        1.68 ± 1.4                                               4.60 ± 0.32                      6.22 ± 0.08   6.51 ± 0.08
  **Day 4**   0.6 ± 0.1                                                        0.42 ± 0.1                                               3.94 ± 0.25                      6.20 ± 0.16   6.67 ± 0.25
  **Day 6**   0.99 ± 0.3                                                       2.89 ± 0.34                                              4.83 ± 0.04                      7.15 ± 0.2    7.63 ± 0.07
  **Day 8**   0.8 ± 0.1                                                        1.46 ± 1.2                                               1.02 ± 0.32                      4.70 ± 0.38   5.24 ± 0.26

\*BDL = below detection limit. All samples BDL were assigned a value of 0.7 log~10~ FFU/mL for culture and 0.3 log~10~ RNA copies/mL for RT-qPCR. Values in brackets depict the standard error.

With immunohistochemistry, RSV antigen was present in areas with microscopic lesions. Within these areas, RSV antigen was present in the entire cytoplasm of epithelial cells lining bronchi and bronchioles, alveoli, and the cytoplasm of occasional macrophages ([Fig 4A](#pone.0143580.g004){ref-type="fig"}). On day 1 p.i. no viral antigen expression was detected in the lungs of infected lambs and was only apparent on day 3 predominantly in the epithelial cells of bronchi and bronchioles when compared to the alveoli. There was an increasing progression of viral antigen expression in both bronchi/bronchioles and alveoli, which reached a peak on day 6 with a marked shift in viral antigen expression occurring in the alveoli. Degenerate and necrotic epithelial cells within lumens of bronchioles also contained viral antigen at days 3, 4, and 6. On day 8, viral antigen expression in lung tissue had decreased substantially ([Fig 4B](#pone.0143580.g004){ref-type="fig"}) consistent with a decline in RSV titers in lung ([Table 3](#pone.0143580.t003){ref-type="table"}).

![Immunohistochemistry and scoring of RSV antigen expression in lambs inoculated with M37 hRSV.\
Immunohistochemistry was used to detect viral antigen using an all-antigens polyclonal antibody for RSV. **(A)** RSV immunoreactivity is shown within epithelial cells lining the bronchioles (brown cells). Bar = 50 μm **(B)** The mean number of virally-infected bronchi/bronchioles and alveoli per field was counted for each day of necropsy.](pone.0143580.g004){#pone.0143580.g004}

Chemokine and cytokine expression in lung tissue {#sec022}
------------------------------------------------

Lung cytokine mRNA expression levels were quantified by RT-qPCR and demonstrated varying patterns of expression in M37 hRSV-inoculated lambs throughout infection. While IL-10 expression levels were highest on day 3 post-infection other chemokines and cytokines had maximal expression at later timepoints (e.g. TGF-β on day 4; IL-8, RANTES and MCP-1α on day 6 and IFN-γ on day 8) ([Fig 5](#pone.0143580.g005){ref-type="fig"}). Similarly, previous results from our laboratory have shown that MCP-1α, MIP-1α, RANTES, IFN-γ, and IL-8 were increased upon RSV-infection in neonatal lambs on day 6 \[[@pone.0143580.ref001]\], whereas the anti-inflammatory mediator, IL-10, was down regulated at day 6 post-infection, but increased on day 3 post-infection \[[@pone.0143580.ref028]\].

![Lung chemokine mRNA expression assessed by RT-qPCR in lambs inoculated with M37 hRSV.\
Lung tissue obtained from each animal was evaluated for the following mRNA targets: surfactant protein A (SP-A), surfactant protein D (SP-D), interleukin 8 (IL-8), interleukin 10 (IL-10), macrophage inflammatory protein 1 alpha (MIP-1α), monocyte chemotactic protein 1 alpha (MCP-1α), tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), interferon beta (IFN-β), interferon gamma (IFN-γ), programmed cell death 1 ligand 1 (PD-L1), and regulated on activation normal T-cell expressed and secreted (RANTES). Mean relative mRNA expression was calculated for each target with respect to each day of necropsy. Relative mRNA expression means: relative to the total amount of RNA loaded per reaction (which is kept constant) and relative to the values established by the standard curves for each target.](pone.0143580.g005){#pone.0143580.g005}

Discussion {#sec023}
==========

This study aimed to determine the time course of M37 hRSV replication in neonatal lambs and the corresponding pathophysiology i.e. clinical signs (wheezing, respiratory distress), airway inflammation, and lung histopathology. Such a time course is difficult to assess in infants since the diagnosis is often only done at the time of or near peak viral titers.

Colostrum-deprived neonatal lambs are highly relevant for the study of RSV infection and may serve as a model of RSV infection in human infants due to the natural susceptibility of lambs to ovine, bovine and human strains of RSV as well as similarities in disease pathogenesis and anatomical, physiological and developmental similarities to that of human infants \[[@pone.0143580.ref013]--[@pone.0143580.ref015]\]. Experimentally, it has been shown that lambs and other ruminants can be infected with human or bovine RSV strains and that the infection induces lung lesions that resemble those observed in human RSV pathology such as bronchiolitis with epithelial cell necrosis, syncytial cell formation, hyperplasia of nearby epithelium and infiltrates of neutrophils with occasional macrophages \[[@pone.0143580.ref001], [@pone.0143580.ref011], [@pone.0143580.ref017], [@pone.0143580.ref029]--[@pone.0143580.ref033]\]. Moreover, RSV infected lambs develop mild to moderate clinical symptoms such as expiratory effort, fever, tachypnea, wheeze, malaise and listlessness \[[@pone.0143580.ref001], [@pone.0143580.ref011], [@pone.0143580.ref017], [@pone.0143580.ref029], [@pone.0143580.ref032]\] and formalin-inactivated RSV vaccination in lambs induces enhanced lesions upon RSV infection \[[@pone.0143580.ref019]\] as observed in infants \[[@pone.0143580.ref034], [@pone.0143580.ref035]\]. To date, and to our knowledge, no study has yet specifically addressed the time course of viral replication, histopathology, airway inflammation, and associated clinical symptomatology (wheezing, respiratory distress) in neonatal lambs following infection by nebulized inhalation of the M37 hRSV strain. The purpose of this study, therefore, was to define the time course of Memphis 37 RSV replication in the lungs of neonatal lambs and the corresponding clinical features and pathophysiology.

Following RSV infection, this study demonstrates that there is robust viral replication as determined by titers and mRNA levels in the lungs, which peaked on day 3, were sustained until day 6 and decreased by day 8. Viral replication was present in the nasal cavity with maximal titers detected at days 3 (cultivatable virus) and 6 (mRNA) post inoculation, but this replication was less robust compared to lung, as viral titers were \~3 Log lower in the nasal wash fluid than in lung on day 3. Such differences in NWF and BALF titers may be related to the administration route which partly bypasses the nasal meatus and also because the sampling of nasal cavity (washes of a cavernous space) differs from solid lung tissue and BALF (taken from a bronchus directly at post mortem). The kinetics of RSV RNA expression levels in BALF and lung tissue displayed a similar profile. Viral antigen expression followed a similar time-profile as titers and mRNA levels, albeit with a delay, and was detected in intact and degenerate/necrotic bronchiolar epithelial cells and ciliated airway epithelial cells in bronchi; cell types that were shown to be permissive to RSV infection \[[@pone.0143580.ref036]--[@pone.0143580.ref041]\], as well as in the cytoplasm of occasional macrophages, consistent with the distribution of virus-infected cells in fatal cases of RSV-infection \[[@pone.0143580.ref033]\]. Viral antigen expression in bronchi/bronchioles and alveoli for each day post-inoculation followed the progression/severity of microscopic lung lesions, gross lung lesions, and respiratory distress.

Microscopically, the bronchiolar epithelia had evidence of necrosis on days 3 and 4 and epithelial hyperplasia, which increased until day 6. The infected bronchiolar cells can, as a result, become degenerate and necrotic and contribute to the cell debris entering and partially occluding the airway lumen. In addition, the necrotic areas and the inflammatory mediators released in this process facilitate neutrophil infiltration and accumulation of seroproteinaceous fluid and mucin, all of which can further occlude the airway lumen. Lymphocytes were first observed by day 3 and 4 and appeared to achieve peak levels by day 6 to 8. Immune cell infiltrates accumulated in the tunica adventitia of bronchi, bronchioles and small blood vessels, and slightly more macrophages were observed in the alveolar and bronchiolar lumens. On day 8 post-infection, airway lumens were observed to contain only occasional neutrophils and macrophages, while infiltrates of lymphocytes and plasma cells remained present in the adventitia, reflecting a change from neutrophilic to lymphocytic and plasmacytic inflammation. The role of lymphocytes in RSV clearance and convalescence has previously been evidenced in human and mouse studies \[[@pone.0143580.ref042]--[@pone.0143580.ref044]\] and the failure to develop an adaptive cytotoxic T lymphocyte response has been proposed to be related to the pathogenesis of RSV infection of the lower respiratory tract \[[@pone.0143580.ref045]\]. Conversely, neutrophils are the most abundant cell type recovered from the respiratory tract in infants-hospitalized for RSV disease \[[@pone.0143580.ref046]--[@pone.0143580.ref048]\] and it has been suggested that they can contribute significantly to epithelial cell damage and to disease severity \[[@pone.0143580.ref049], [@pone.0143580.ref050]\].

In addition to inflammatory cell influx in the lungs, it has been shown that chemokines and cytokines, such as IL-8, RANTES, MIP-1α, IL-6 and IL-10 are increased in RSV-infected infants \[[@pone.0143580.ref049], [@pone.0143580.ref051]--[@pone.0143580.ref057]\] and likely to promote the intense inflammatory process present in the airways of these infants. For this reason, we sought to investigate the time course of chemokine expression in lung tissue from RSV-infected lambs. Expression of proinflammatory chemokines and cytokines such as IL-8, IFN-γ, IFN-β, MCP-1α, MIP-1α and TNF-α or anti-inflammatory cytokines such as IL-10 was detected and was consistent with previously published data \[[@pone.0143580.ref001], [@pone.0143580.ref028]\]. Peak expression of IL-8 was present at day 6 post-infection and coincided with peak neutrophil influx in the lungs of RSV-infected lambs which indicates that the increased chemokine expression contributed to neutrophil infiltration into the site of intense RSV infection, in accordance with the role of IL-8 in neutrophil chemotaxis \[[@pone.0143580.ref007]\]. In contrast, IFN-γ expression, a cytokine mainly produced by NK cells and activated CD4^+^ and CD8^+^ T cells that promotes cell-mediated immune responses to intracellular pathogens, was maximal at day 8 post-infection at a time when peak lymphocyte lung infiltration was noted. Taken together, this data suggests that RSV infection in neonatal lambs results in an initial innate inflammatory response, the peak of which coincides to that of peak disease, and is characterised by IL-8 secretion and neutrophil influx. During the transition from the initial inflammatory response, there is infiltration of lymphocytes and, as the disease resolves, the inflammatory response is characterised by IFN-γ secretion and continued lymphocyte influx. Interestingly, a suppressed lymphocyte function and increased plasma IL-8 levels were shown to be markers of severe disease in RSV bronchiolitis \[[@pone.0143580.ref058]\].

The most interesting results, however, obtained in the current study were those related to the clinical parameters. Infants with RSV-disease typically develop clinical manifestations such as bronchiolitis and pneumonia symptoms of which include wheezing, crackles, rhonchi, tachypnea, nasal flaring, and intercostal muscle retractions \[[@pone.0143580.ref059], [@pone.0143580.ref060]\]. In our study, the neonatal lambs developed respiratory distress (forced expiration, abdominal breathing and wheeze) following RSV-infection consistent with previous reports \[[@pone.0143580.ref001], [@pone.0143580.ref018]\]. The progression of respiratory distress coincided with that of viral replication (titers, viral RNA and viral antigen expression), lung gross viral lesions, and histopathological changes. The resultant partial occlusion of the small airways by sloughed epithelial cells, inflammatory cells, respiratory secretions and mucous plugs as observed microscopically may lead to air trapping, lung hyperexpansion and increased airway resistance causing respiratory distress \[[@pone.0143580.ref061]\]. The deterioration of lung function and clinical symptomatology thus appears to be a direct effect of viral replication and its induction of bronchiolar/lung pathology. In experimentally-infected adults, a similar close temporal association between onset, peak, and clearance of viral replication, and the onset, peak, and resolution of the disease, has been described as well. However, viral replication and disease are limited to the upper airways in this human model \[[@pone.0143580.ref022]\].

This viral kinetic study of M37 hRSV in newborn lambs establishes a baseline of clinical features and pathology in a model where RSV infection and the consequences thereof resembles that of human infant RSV disease in the lower airways and may serve as a valuable tool to assess vaccine and antiviral drug safety and efficacy.
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